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Abstract
Background: Aß peptides are often considered as catabolic by-products of the amyloid ß protein precursor (APP), with
unknown physiological functions. However, several biological properties have been tentatively attributed to these peptides,
including a role in vasomotion. We assess whether plasma Aß peptide levels might be associated with systolic and
diastolic blood pressure values (SBP and DBP, respectively).
Methodology/Principal Findings: Plasma Aß1-40 and Aß1-42 levels were measured using an xMAP-based assay in 1,972
individuals (none of whom were taking antihypertensive drugs) from 3 independent studies: the French population-based
3C and MONA-LISA (Lille) studies (n=627 and n=769, respectively) and the Australian, longitudinal AIBL study (n=576). In
the combined sample, the Aß1-42/A ß 1-40 ratio was significantly and inversely associated with SBP (p=0.03) and a similar
trend was observed for DBP (p=0.06). Using the median age (69) as a cut-off, the Aß1-42/Aß1-40 ratio was strongly associated
with both SBP and DBP in elderly individuals (p=0.002 and p=0.03, respectively). Consistently, a high Aß1-42/A ß 1-40 ratio
was associated with a lower risk of hypertension in both the combined whole sample (odds ratio [OR], 0.71; 95% confidence
interval [CI], 0.56-0.90) and (to an even greater extent) in the elderly subjects (OR, 0.53; 95% CI, 0.37–0.75). Lastly, all these
associations appeared to be primarily driven by the level of plasma Aß1-40.
Conclusion: The plasma Aß1-42/Aß1-40 ratio is inversely associated with SBP, DBP and the risk of hypertension in elderly
subjects, suggesting that Aß peptides affect blood pressure in vivo. These results may be particularly relevant in Alzheimer’s
disease, in which a high Aß1-42/Aß1-40 plasma ratio is reportedly associated with a decreased risk of incident disease.
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Introduction
Aß peptides are the main component of ß-amyloid deposits in
the brains of Alzheimer’s disease (AD) patients. Many different cell
types from the brain and the peripheral tissues produce these
peptides. They are catabolic by-products of the amyloid ß protein
precursor (APP) and do not have a known physiological function.
However, several lines of evidence suggest that Aß peptides may
have biological functions by acting as ligands for various receptors
and other molecules [1–3]. The peptides are transported between
tissues and across the blood brain barrier via complex trafficking
pathways [4]. Lastly, at physiological concentrations, the peptides
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modulation [7], antimicrobial [8] and/or vasoconstriction prop-
erties [9].
With respect to vascular tone, Aß peptides are produced by the
vascular smooth muscular cells (SMCs) [10] involved in blood
pressure (BP) control and are known to have vasoactive properties
[11]. Indeed, in in vitro studies, Aß peptides enhance constriction of
isolated vessels via the release of endothelin 1 [12], a vasoactive
peptide which produces smooth muscle contraction in vivo [11].
Taken as a whole, these observations suggest that the Aß peptides
may affect BP control. Interestingly, the Aß peptides decrease
cerebral blood flow and volume in rodents [13–15].
In the present study, we hypothesized that plasma Aß peptide
concentrations may be associated with variations in systolic and/or
diastolic blood pressure values (SBP and DBP, respectively). To
this end, we analysed a pooled analysis of 1972 individuals from
three independent cohorts in which plasma Aß1-40 and Aß1-42
concentrations were available.
Methods
The three samples were selected according to the availability of
(i) plasma Aß concentration assays using the same method (the
INNO-BIA plasma Aß forms assay; this point is of particular
importance, since the assay methodology can significantly
influence interpretation of the data [16]), (ii) SBP and DBP
measurements; (iii) information on demographic variables, smok-
ing and medication use.
Populations
Written, informed consent was obtained from study partici-
pants. The study protocols for all populations were reviewed and
approved by the appropriate independent ethics committees in
each country. The institutional ethics committees of Austin
Health, St Vincent’s Health, Hollywood Private Hospital and
Edith Cowan University granted ethics approval for the AIBL
study. The institutional ethics committees of the Kremlin-Bicetre
Hospital granted ethics approval for the 3C study. The
institutional ethics committees of the Lille Hospital granted ethics
approval for the MONA-LISA study.
The 3C Study is a population-based, prospective study of the
relationship between vascular factors and dementia [17]. It has
been carried out in three French cities: Bordeaux (southwest
France), Montpellier (southern France) and Dijon (central eastern
France). A sample of non-institutionalised, over-65 subjects was
randomly selected from the electoral rolls of each city between
January 1999 and March 2001. In the present work, the study
population was based on a sub-cohort of 1254 subjects randomly
selected from the source sample totalling 8,414 individuals (i.e. a
sampling ratio of 15%) stratified by centre, 5-year age class and
gender. Aß plasma concentrations were measured in the whole
sample [18]. Individuals taking antihypertensive drugs were
excluded from our analysis (n=615). Individuals for whom at
least one Aß plasma concentration or co-variable measurement
was missing were also excluded (n=4), together with individuals
exhibiting at least one aberrant Aß plasma concentration
measurement (n=8). These selection steps allowed us to define a
sample of 627 individuals.
The MONA-LISA (LILLE) study is an epidemiological, cross-
sectional, population-based study performed in the Lille urban
area in northern France. Inhabitants aged 35-74 years were
randomly sampled from electoral rolls after stratification by town
size, gender and 10-year age groups (n=1,602) [19]. Only
individuals older than 45 years old were selected (n=1217) and
blood samples were obtained from 1201 individuals. Our analysis
excluded individuals taking antihypertensive drugs (n=422), those
for whom at least one Aß plasma concentration, SBP, DBP or co-
variable measurement was also missing (n=7) and those exhibiting
at least one aberrant Aß plasma concentration measurement
(n=3). These selection steps allowed us to define a sample of 769
individuals.
The Australian Imaging Biomarkers and Lifestyle (AIBL) study
of ageing has been described elsewhere [20]. It is a longitudinal
study performed in Perth and Melbourne (Australia). A total of
1,112 volunteers constituted the AIBL inception cohort. Our
analysis excluded individuals taking antihypertensive drugs
(n=375), those for whom at least one Aß plasma concentration,
SBP, DBP or co-variable measurement was also missing (n=147)
and those exhibiting at least one aberrant Aß plasma concentra-
tion measurement (n=14). Again, these selection steps enabled us
to define a sample of 576 individuals from the AIBL cohort.
Amyloid beta peptide assay
Fasting plasma samples were collected in tubes containing
sodium EDTA as an anticoagulant. Following centrifugation,
plasma samples were aliquoted into polypropylene tubes, stored at
–80uC and only thawed immediately prior to Aß quantification.
The plasma Aß peptide assay was performed using the INNO-BIA
plasma Aß forms assay (Innogenetics, Ghent, Belgium) based on
the multiplex xMAP technique with a LABScan-100 system
(Luminex BV, The Netherlands). The 3C and MONA-LISA
(LILLE) studies were analyzed in the same centre (INSERM
U837, Alzheimer & Tauopathies, Lille, France).
Blood pressure measurements and co-variables
During inclusion in the 3C study, BP was measured twice after 5
minutes in the seated position by using a standard cuff placed
around the right arm and an electronic monitor (OMRON M4).
In the MONA-LISA (LILLE) population, SBP and DBP were
measured after the subject had been seated for at least 10 min with
an automatic sphygmomanometer (OMRON 705IT) and an
appropriately sized cuff, with the arm at heart level. In the AIBL
study, BP for each participant was measured between 8.15 am and
9.30 am and after 10 minutes in the seated position by using the
Welch Allyn ‘‘DuraShock’’ handheld unit (DS65). If a measure-
ment was high (.140/90) or low, the procedure was repeated after
10 minutes.
The average of two measurements (available for 84% of the
study sample) was used for analysis, whenever possible. Hyper-
tension was defined as a SBP $140 mm Hg or DBP $90 mmHg
(n=337 in the 3C sample, n=307 in the MONA-LISA (LILLE)
sample and n=270 in the AIBL sample).
Age, centre and gender were always used as adjusting factors.
Several other co-variables were also considered as potential
confounders: smoking status (current or not), plasma cholesterol
(total, high-density lipoprotein), creatinine levels and body mass
index (BMI, as defined by the Quetelet equation).
Statistics
The data were analysed using SAS statistical software (release
9.1, SAS Institute Inc., Cary NC, USA). In each centre, each
quantitative variable was transformed into a z-score (equal to
(observed value minus the sample mean), divided by the sample
standard deviation). The relationships between the Aß1-40,A ß 1-42
and Aß1-42/Aß1-40 z-scores on one hand and the SBP or DBP z-
scores on the other were assessed using a general linear model
(GLM) adjusted for age, centre and gender (model 1). Analyses
were subsequently adjusted for other confounders, as defined
Blood Pressure and Plasma Aß Peptides
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creatinine z-score and BMI z-score (model 2). Interactions
between Aß1-42/Aß1-40 z-scores, SBP or DBP z-scores and age
or gender were tested in a GLM adjusted as for model 2.
We analysed the association of Aß1-40,A ß 1-42 and Aß1-42/Aß1-40
z-scores with the risk of hypertension. Aß1-40,A ß 1-42 and Aß1-42/
Aß1-40 z-scores tertiles were defined and the lowest was used as a
reference in a logistic regression model. Odds ratios were
systematically adjusted for centre, age, gender, smoking status,
cholesterol (total, high-density lipoprotein), creatinine levels and
BMI z-scores (model 2).
Results
The characteristics of the three independent, constituent samples
arepresentedinTable1.Therewasa statisticallysignificant,inverse
association between plasma Aß1-42/Aß1-40 and SBP (p=0.03;
Table 2). A similar trend was observed for DBP (p=0.06; Table 2).
We also looked at whether or not Aß1-42/Aß1-40 was associated with
the risk of hypertension. In fact, individuals in the upper Aß1-42/
Aß1-40 tertile had a 1.4-fold lower risk of hypertension than subjects
in the lower tertile (Table 3).
We next searched for potential interactions between age, gender
and the associations described above. We observed significant
interactions with age when analysing the association between SBP
or the risk of hypertension and plasma Aß1-42/Aß1-40 (p=0.02 and
p=0.04, respectively). These observations are particular relevant,
since BP and plasma Aß concentrations are already known to be
strongly age-dependent [18,21].
We thus stratified the combined sample using the median age
(.69) as a cut-off and observed more pronounced inverse
associations between BP levels and Aß1-42/Aß1-40 in the elderly
individuals (Table 4). Importantly, the association of Aß1-42/Aß1-40
with BP levels appeared to be primarily linked to plasma Aß1-40
levels (Table 4). Similarly, this association was even more
pronounced in the elderly, where individuals in the upper Aß1-42/
Aß1-40 tertile had a 2-fold lower risk of hypertension (Table 3). The
plasma Aß1-42/Aß1-40 ratio’s associations with hypertension again
appeared to be mainly driven by plasma Aß1-40 in the oldest
subjects. Individuals in the upper Aß1-40 z-score tertile had a
greater risk of suffering from hypertension (OR=1.61, 95% CI
[1.09–2.39], p=0.01), whereas no association with the Aß1-42 z-
score was found (OR=1.03, 95% CI [0.74–1.45], p=0.85).
Importantly, all the reported associations appeared homogenous
and in the same direction in the three samples when analysed
separately (Table S1 and S2) and remained significant when pairs
of populations were compared in a sensitivity analysis (data not
shown).
Discussion
Here, we have shown that an elevated plasma Aß1-42/Aß1-40
ratio is significantly associated with low SBP and DBP values. In
the elderly, we estimate that a 0.01 unit increment in Aß1-42/
Aß1-40 was associated with a 0.2960.09 mmHg decline in SBP
and a 0.1060.05 mmHg decline in DBP. Consistently, an elevated
Aß1-42/Aß1-40 plasma ratio was also associated with a lower risk of
hypertension in the elderly.
Table 2. Associations between plasma Aß peptides and SBP
& DBP values.
Combined
sample Model 1 Model 2
Aß1-40 ßp ß p
SBP z-score +0.00660.023 0.80 +0.00660.023 0.80
DBP z-score +0.01160.026 0.65 +0.00560.023 0.83
Aß1-42 ßp ß p
SBP z-score 20.03660.021 0.09 20.03960.021 0.10
DBP z-score 20.02360.022 0.31 20.03160.022 0.16
Aß1-42/Aß1-40 ßp ß p
SBP z-score 20.04460.022 0.04 20.04560.021 0.03
DBP z-score 20.03760.022 0.10 20.04060.022 0.06
Data are ß coefficients 6 95% CI.
Model 1: Adjusted for age, gender, centre.
Model 2: Adjusted for age, gender, centre, smoking status, total cholesterol z-
score, HDL z-score, creatinine z-score and BMI z-score.
doi:10.1371/journal.pone.0018536.t002
Table 1. Baseline sociodemographic variables and potential confounding factors in the 3C, ABLI and MONA-LISA (LILLE)
populations (individuals not taking antihypertensive drugs; for details, see the Materials and Methods section).
3C study (n=627) AIBL study (n=576) MONA-LISA study (n=769)
Age (years) 73.165.3 71.667.8 58.168.2
% women 59.7% 57.8% 49.4%
Smoking (% current) 6.7% 3.0% 18.6%
Body mass index (kg/m
2) 24.963.5 25.564.1 26.564.5
Plasma HDL cholesterol (mmol/L) 1.6760.41 1.7060.44 1.5060.39
Plasma cholesterol (mmol/L) 6.061.0 5.761.1 5.8761.1
Plasma creatinine 80.5615.6 81.1617.3 85.0615.8
SBP (mmHg) 141.9620.4 136.5614.7 136.5618.6
DBP (mmHg) 81.3611.0 78.069.3 82.2610.6
Plasma Aß1-40 (pg/ml) 227.8648.0 153.6640.4 205.4642.8
Plasma Aß1-42 (pg/ml) 37.5610.3 31.3610.0 36.7611.45
Plasma Aß1-42/A ß 1-40 0.16960.049 0.20960.059 0.18460.069
doi:10.1371/journal.pone.0018536.t001
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SBP, DBP and hypertension appeared to be mainly driven by
plasma Aß1-40 in the oldest subjects. Our observation of an
association between plasma Aß1-40 and SBP agrees with the report
of a similar trend (in a small sample) by Abdullah et al [22]. The
mechanisms underlying this preferential association may be
related to the Aß1-40 peptide’s properties on vascular vessels.
Earlier studies have shown that Aß1-40 peptides can constrict
cerebral blood vessels in vitro
9 and decrease cerebral flow and
cerebral blood volume in vivo [10–12]. and that Aß1-40 has greater
vasoconstriction effects on the cerebral vasculature than Aß1-42
does [12]. Furthermore, in rodents, injection of Aß1-40 into the tail
modulates cerebral blood flow and volume, suggesting that Aß
peptides have a direct impact on blood pressure. Finally, Aß
peptides have been described to potentially modulate the
vasoactivity of the rat aorta [23]. Thus, by extension our
observation of an association between an elevated Aß1-42/Aß1-40
ratio and low SBP may be related to the properties of Aß1-40 on
vascular wall in the elderly. In vitro and in vivo experiments will be
needed to underpin this epidemiological observation and to extend
knowledge of the Aß peptides’ vasoactivity from the cerebral
vasculature to the vascular system as a whole. Alternatively, we
cannot rule out the possibility that the plasma Aß1-42/Aß1-40 ratio
is merely a marker of other parameters involved in BP variations
or that the plasma Aß1-42/Aß1-40 association with BP is a
consequence of BP variations by themselves. These possibilities
may help explain the stronger association of the plasma Aß1-42/
Aß1-40 ratio with SBP and DBP in the elderly individuals. Age-
related arterial wall stiffening may lead indirectly to subtle changes
in APP metabolism in the SMCs (one of the main non-brain cell
types able to produce Aß peptides). Again, only in vitro and in vivo
experiments will be able to clarify this question.
Nonetheless, and notwithstanding the consistent effects that we
have observed, our study suffered from a number of limitations.
Firstly, quantification of Aß peptides in plasma is not fully
standardized and it varied from one centre to another (Table 1).
Even though centre-to-centre variations are well known for
quantitative variables, we cannot rule out the possible presence
of assay-related of bias. Therefore, in order to minimize between-
centre variability, we transformed the data in to z-scores prior to
our statistical analyses. Secondly, it is still unclear whether the
assay used here does indeed quantify all the various free, bound,
monomeric and oligomeric forms of plasma Aß1-40 and Aß1-42
peptides. Accordingly, we may only have a partial picture of the
Aß1-40 and Aß1-42 concentrations in plasma - a picture which is
Table 4. Associations between plasma Aß peptides and SBP & DBP values.
#69 years of age Model 1 Model 2
Aß1-40 ßp ß p
SBP z-score 20.04660.030 0.12 20.04960.029 0.10
DBP z-score 20.02560.031 0.41 20.03560.030 0.24
Aß1-42 ßp ß p
SBP z-score 20.02860.030 0.34 20.03660.030 0.23
DBP z-score 20.00860.031 0.80 20.03260.031 0.54
Aß1-42/Aß1-40 ßp ß p
SBP z-score +0.01360.022 0.56 +0.00660.022 0.78
DBP z-score 20.01060.024 0.67 20.01360.022 0.57
.69 years of age
Aß1-40 ßp ß p
SBP z-score +0.09960.034 0.004 +0.09860.035 0.005
DBP z-score +0.06660.035 0.06 +0.06660.035 0.07
Aß1-42 ßp ß p
SBP z-score 20.03260.031 0.30 20.03960.031 0.21
DBP z-score 20.02860.031 0.38 20.03260.031 0.30
Aß1-42/Aß1-40 ßp ß p
SBP z-score 20.09060.030 0.003 20.09260.030 0.002
DBP z-score 20.06460.031 0.04 20.06760.031 0.03
Data are ß coefficients 6 95% CI.
Model 1: Adjusted for age, gender, centre.
Model 2: Adjusted for age, gender, centre, smoking status, total cholesterol z-score, HDL z-score, creatinine z-score and BMI z-score.
doi:10.1371/journal.pone.0018536.t004
Table 3. Associations between the plasma Aß 1-42/A ß1-40
ratio and hypertension.
Aß1-42/A ß 1-40 z-score
Risk of
hypertension
1
st tertile 2
nd tertile 3
rd tertile p
Whole sample 1.00 (ref) 0.81
(0.65–1.03)
0.71
(0.56–0.90)
0.004
.69 years of
age
1.00 (ref) 0.69
(0.49–0.98)
0.53
(0.37–0.75)
0.0003
The odds ratio (95% CI) for hypertension (n=914) was adjusted for age, gender,
centre, smoking status, total cholesterol z-score, HDL z-score, creatinine z-score
and BMI z-score.
doi:10.1371/journal.pone.0018536.t003
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analyses. In order to minimize this problem, we analysed three
independent cohorts in which the same plasma Aß peptide assay
method had been used. Interestingly, the assay performed in the
present study uses xMAP technology to quantify several epitopes
and thus several different Aß species. Furthermore, we observed a
strong correlation between plasma Aß1-40 and Aß1-42 in all the
populations analysed (data not shown) - indicating that the plasma
Aß peptide concentrations are representative of the physiological
processes leading to Aß peptide production (i.e. APP metabolism).
Furthermore, sensitivity analyses indicated that the observed
results are homogeneous for the elderly individuals in the different
studies and support the existence of a real impact of Aß peptides
on BP values and hypertension (Tables S1 and S2).
Our data may be of particular interest in the field of dementia.
On the epidemiological level, an increased risk of dementia in
individuals with high BP (and especially very high SBP) has been
reported [24], although there is no clear consensus to indicate that
raised BP in later life is a risk factor in dementia [25–27].
Furthermore, use of antihypertensive agents was suggested to
reduce the risk of dementia and cognitive decline observed in
clinical trials [28]. Interestingly, we and others have observed that
an elevated Aß1-42/Aß1-40 ratio is strongly associated with a
decreased risk of incident Alzheimer’s disease and mixed/vascular
dementia [18,29]. Consequently, we can justifiably postulate that
high plasma Aß1-42/Aß1-40 may reduce and/or delay the risk of
developing dementia in the elderly by decreasing SBP and
lowering the risk of hypertension. Our data might be also
consistent with the finding that plasma Aß1-40 is associated with
microvascular brain injury in subjects with AD, mild cognitive
impairment or cerebral amyloid angiopathy [30].
In conclusion, our data support the potential vasoactive properties
of the Aß peptides and suggest that the latter are able to subtly
modulate BP in the elderly. Furthermore, these observations may offer
new opportunities for better understanding the vascular component of
dementia in general and Alzheimer’s disease in particular.
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